Ana Martin-Villalba

from Wikipedia, the free encyclopedia

Ana Martin-Villalba (born November 13, 1971 in Madrid ) is a Spanish doctor and cancer researcher.

Live and act

From 1989 she studied medicine at the University of Murcia and at the University of Leeds . She did her PhD in 1998 at the Institute for Physiology and Pathophysiology at the University of Heidelberg .

She was an assistant doctor in neurology at the Heidelberg University Hospital, then carried out research at the Institute for Physiology and Pathophysiology, was a visiting scientist at the University of Tor Vergata in Rome from 1998/99 and was group leader in the immunogenetics department of the German Cancer Research Center in Heidelberg with Peter Krammer from 1999 . She also taught at the University of Heidelberg, where she completed her habilitation in 2007. Since 2011 she has been a professor in the department of molecular neurobiology at the DKFZ (neurobiology of brain tumors).

She and her group are investigating the role of the CD-95 signaling pathway, which plays a role in the migration and growth of cancer cells (cancer stem cells) and cells of the immune system as well as in the nervous system, as well as in the survival and differentiation of stem cells (which are about important in the healing of external injuries and neural regeneration). In particular, they investigated its role in neurodegenerative diseases in which CD 95 triggers inflammation ( autoimmune diseases , Parkinson's disease ).

Awards

In 2006 she received the Paul Ehrlich and Ludwig Darmstaedter Prize for Young Scientists and the Heinz Maier Leibnitz Prize . From 2017 to 2018 she was the President of the German Stem Cell Network (GSCN). In 2020 Martin-Villalba was elected to the European Molecular Biology Organization .

Web links

Individual evidence

  1. ↑ a b CV . DFG. Retrieved January 17, 2016.
  2. ↑ Ischemia induced apoptosis in the mammalian brain crucially correlates with long lasting phosphorylation of c-Jun, suppression of ATF-2 and expression of the death inducing ligands CD95-Ligand and TRAIL / presented by Ana Martín-Villalba . In: DNB, catalog of the German National Library . 1998. Retrieved January 17, 2016.
  3. ↑ CD for cluster of differentiation , also Fas receptor or APO-1
  4. ↑ S Kleber: Yes and PI3K bind CD95 to signal invasion of glioblastoma. . In: Cancer Cell . 13, No. 3, March 2008, pp. 235-48. PMID 18328427 .
  5. ^ Future of stem cell research. Accessed March 7, 2019 (German).
personal data
SURNAME Martin-Villalba, Ana
BRIEF DESCRIPTION Spanish cancer researcher and doctor
DATE OF BIRTH November 13, 1971
PLACE OF BIRTH Madrid